Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT05933967

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

Led by Shandong Cancer Hospital and Institute · Updated on 2023-08-15

31

Participants Needed

2

Research Sites

186 weeks

Total Duration

On this page

Sponsors

S

Shandong Cancer Hospital and Institute

Lead Sponsor

T

The First Affiliated Hospital of Nanchang University

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double expression DLBCL.

CONDITIONS

Official Title

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Newly diagnosed double expression diffuse large B-cell lymphoma
  • Age between 18 and 70 years
  • ECOG performance status between 0 and 2
  • Ann Arbor stage II to IV
  • Meet clinical trial laboratory testing standards
  • Life expectancy of at least 3 months
Not Eligible

You will not qualify if you...

  • Lymphoma involving the central nervous system
  • Uncontrolled cardiovascular or cerebrovascular diseases
  • Coagulopathy or connective tissue diseases
  • Uncontrolled infections including HBV, HCV, or HIV/AIDS
  • Preparing for transplantation
  • Pregnancy or active breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

The First Ailliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Actively Recruiting

2

Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences

Jinan, Shandong, China

Actively Recruiting

Loading map...

Research Team

Z

zengjun Li

CONTACT

D

Dan Liu

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma | DecenTrialz